Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.

Future Oncol · 2020 · PMC8459336 · PMID 32363929

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.2000

boldest claim

The sentences

approached significancep = 0.053so close (0.05 < p ≤ 0.1)

However, the MSKCC prognostic group factors approached significance in the mRNA analysis set (p = 0.053), with more patients in the poor-risk group in axitinib-treated patients (38.2%) compared with those in the sorafenib-treated group (12.1%; Table 1 ).

also in 8,237 other papers

a slight trendp < 0.2not close (p > 0.1)

There was a slight trend (p < 0.2), but no significant difference in median OS in patients with CD68 + cell density ≥median versus <median (22.6 vs 17.8 months; HR: 0.6; p = 0.173).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.